Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression.

ABSTRACT: Propranolol, a widely used non-selective beta-adrenergic receptor blocker, was recently shown to display anticancer properties. Its potential to synergize with certain drugs has been also outlined. However, it is necessary to take into account all the properties of propranolol to select a drug that could be efficiently combined with. Propranolol was reported to block the late phase of autophagy. Hence, we hypothesized that in condition enhancing autophagy flux, cancer cells should be especially sensitive to propranolol. 2DG, a glycolysis inhibitor, is an anti-tumor agent having limited effect in monotherapy notably due to induction of pro-survival autophagy. Here, we report that treatment of cancer cells with propranolol in combination with the glycolysis inhibitor 2DG induced a massive ac

SUBMITTER: Brohee L 

PROVIDER: S-EPMC5935740 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature